Vanguard Group Inc Glycomimetics Inc Call Options Transaction History
Vanguard Group Inc
- $5.12 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding GLYC
# of Institutions
44Shares Held
25.7MCall Options Held
1.94MPut Options Held
153K-
Bvf Inc San Francisco, CA9.54MShares$4.01 Million0.08% of portfolio
-
Artal Group S.A. Luxembourg, N48.59MShares$3.61 Million0.15% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny827KShares$347,2770.0% of portfolio
-
Goldman Sachs Group Inc New York, NY804KShares$337,8230.0% of portfolio
-
Black Rock Inc. New York, NY723KShares$303,7370.0% of portfolio
About GLYCOMIMETICS INC
- Ticker GLYC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,423,900
- Market Cap $22M
- Description
- GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...